Novel Combination of Arsenic Trioxide (As 2 O 3 ) Plus Resveratrol in Inducing Programmed Cell Death of Human Neuroblastoma SK-N-SH Cells.

Aim: Arsenic trioxide (As ₂ O ₃ ), known as pi-shuang and the most toxic compound in traditional Chinese medicine, has been used as an antitumor agent for thousands of years. Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a natural phenol that has significant anti-bacterial, anti-fungaI and antiaging activities. Our study aimed to examine the combined anticancer effects of As ₂ O ₃ and resveratrol against human neuroblastoma SK-N-SH cells, and elucidate the underlying intracellular signaling.
Materials and Methods: SK-N-SH cells were treated with an extremely low-dose (2-4 μM) of As ₂ O ₃ alone or combined with 75 μg/ml resveratrol for further comparisons. Cell viability, apoptotic signaling as well as synergistic cytotoxic effects were estimated using the MTT assay, microscopy observation, flow cytometric analysis for loss of mitochondrial membrane potential (MMP) and reactive oxygen species (ROS), and typical quantitative western blotting analysis. Student's t-test, and one- and two-way analysis of variance (ANOVA) were used for examination of significant differences.
Results: The combined treatment was more effective than single treatment of As ₂ O ₃ or resveratrol alone in suppressing cell viability, which correlated with the elevation of ROS levels. The intracellular mechanisms of cytotoxicity of As ₂ O ₃ plus resveratrol were revealed as ROS accumulation and relative decrease of MMP, leading to activation of caspase-3 and -9, but not of caspase-1, -7 and-8. Combination treatment reduced the expression of B-cell lymphoma 2 (BCL2), BH3 interacting domain death agonist (BID), and BCL-x/L.
Conclusion: Combined treatment at extremely low concentration of two agents from natural products, As ₂ O ₃ and resveratrol, has high potential as a cocktail of anticancer drugs for neuroblastoma.
(Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)